Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection ModelBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelBrian D VanScoy, Rodrigo E Mendes, Mariana Castanheira, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 23, 2021
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumoniaAntoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2016
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trialsMyra W Popejoy, David L Paterson, Daniel Cloutier, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.
The Lancet. Infectious Diseases|September 3, 2019
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialWilliam O'Riordan, Carrie Cardenas, Elliot Shin, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with CeftolozaneBrian Vanscoy, Rodrigo E Mendes, Jennifer McCauley, et al.
Pageof 4